Stocks Health care GILD
NASDAQ · Health careGilead Sciences, Inc. (GILD)
Gilead Sciences, Inc. brought in $30.5B of revenue over the twelve months to June 30, 2026, up 5.5% from a year earlier. It posted a net loss of $3.2B. Operating cash flow minus capital spending left $9.5B of free cash flow in fiscal 2025. At June 30, 2026 it held $3.2B in cash against $26.2B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Gilead Sciences, Inc. does
Gilead Sciences discovers, develops, and commercializes medicines for life-threatening diseases. It produces antiviral therapies used in the treatment and prevention of HIV and hepatitis B and C, as well as oncology and cell therapy treatments. Its products are purchased by pharmacies, hospitals, wholesale distributors, and healthcare providers. Its shares trade on NASDAQ under the ticker GILD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $29.4B | $8.5B | $6.78 | $9.5B |
| 2024 | $28.8B | $480M | $0.38 | $10.3B |
| 2023 | $27.1B | $5.7B | $4.50 | $7.4B |
| 2022 | $27.3B | $4.6B | $3.64 | $8.3B |
| 2021 | $27.3B | $6.2B | $4.93 | $10.8B |
| 2020 | $24.7B | $123M | $0.10 | $7.5B |
Where GILD ranks in Health care
Dividends
Gilead Sciences, Inc. declared $3.16 per share in fiscal 2025. At the current price that is a yield of 2.09%. It paid out $4B in cash dividends, 47% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $3.16 | $4B | 47% |
| 2024 | $3.08 | $3.9B | 816% |
| 2023 | $3.00 | $3.8B | 67% |
| 2022 | $2.92 | $3.7B | 81% |
| 2021 | $2.84 | $3.6B | 58% |
| 2020 | $2.72 | $3.4B | 2,804% |
Latest SEC filings
What Gilead Sciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 26, 2026Form N-PX filing N-PX
- August 7, 2026Activist stake changed SCHEDULE 13D/A
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 4, 2026
- August 3, 2026Form 13F-HR filing 13F-HR
- May 27, 2026Activist stake changed SCHEDULE 13D/A
- May 20, 2026
- May 18, 2026
- May 14, 2026
What is GILD worth? A DCF from its reported cash flow
Insider trades
What the people running Gilead Sciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $5.8M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 22, 2026 | Burkhart ErinSVP, Controllership | Exercised options | 2,223 | - |
| September 22, 2026 | Burkhart ErinSVP, Controllership | Shares withheld for tax | 768 | $117.3K |
| September 15, 2026 | Dickinson Andrew DChief Financial Officer | Soldpre-planned (10b5-1) | 3,000 | $435.9K |
| September 15, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Soldpre-planned (10b5-1) | 1,600 | $229.9K |
| September 15, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Soldpre-planned (10b5-1) | 800 | $115.6K |
| September 15, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Soldpre-planned (10b5-1) | 600 | $87.2K |
| September 10, 2026 | Dickinson Andrew DChief Financial Officer | Exercised options | 2,797 | - |
| September 10, 2026 | Dickinson Andrew DChief Financial Officer | Shares withheld for tax | 1,347 | $195.1K |
| September 10, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Exercised options | 8,780 | - |
| September 10, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Shares withheld for tax | 4,230 | $612.5K |
| September 10, 2026 | Berger DietmarChief Medical Officer | Exercised options | 533 | - |
| September 10, 2026 | Berger DietmarChief Medical Officer | Shares withheld for tax | 263 | $38.1K |
| September 10, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Exercised options | 2,797 | - |
| September 10, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Shares withheld for tax | 1,347 | $195.1K |
| September 10, 2026 | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Exercised options | 590 | - |
Questions about GILD
What does Gilead Sciences, Inc. do?
Gilead Sciences discovers, develops, and commercializes medicines for life-threatening diseases. It produces antiviral therapies used in the treatment and prevention of HIV and hepatitis B and C, as well as oncology and cell therapy treatments. Its products are purchased by pharmacies, hospitals, wholesale distributors, and healthcare providers. Its shares trade on NASDAQ under the ticker GILD.
Is Gilead Sciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $3.2B on revenue of $30.5B.
How much revenue does Gilead Sciences, Inc. make?
Over the twelve months to June 30, 2026 Gilead Sciences, Inc. reported revenue of $30.5B. That is 5.5% more than a year earlier.
When did Gilead Sciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 23, 2026.
Similar companies
Compare GILD with
Follow GILD
Get an email when Gilead Sciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow GILD: get an email when it filesWhere the numbers come from
Financial figures are the values Gilead Sciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.